IT

Intra-Cellular Therapies IncNASDAQ ITCI Stock Report

Last reporting period 30 Sep, 2024

Updated 21 Nov, 2024

Last price

Market cap $B

7.98

Middle

Exchange

XNAS - Nasdaq

View Section: Company Analysis

Intra-Cellular Rating

IT

ITCI stock rating score is 47/100. Intra-Cellular is aExtremely Risky Investment.

The in-depth assessment covers such aspects as the profitability and solvency of the company, management efficiency, and growth sustainability. Our rating serves as an answer to whether the company`s shares are generally reasonable for purchase. The higher company rating score is, the more stock is attractive for investment.

Eyestock Rating

Last update 01.11.2024

47/100

Low score

Rating Breakdown

  • Profitability score

    1

    /25

  • Solvency score

    46

    /25

  • Efficiency score

    -19

    /25

  • Stability score

    18

    /25

Intra-Cellular Therapies Inc Rewards and Warnings

The assessment of the quality of a business is based on quantitative analysis of 10 key financials taken from the company's statements. Pay close attention to the cons, if any, before making a decision.

Financial

Check

Value

Net Profit Margin

-14 %

Earnings quality

Gross Margin

92 %

Intra-Cellular Therapies Inc's Historical Rating

How has the company's valuation changed in the past?

A quick analysis will help you understand how stable financial indicators are overall.


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Discover High-rated Companies


View Section: Valuation